Consistent with these findings, a recent study in patients with ER+/HER2− breast cancer treated with neoadjuvant fulvestrant with or without enza demonstrated that AR inhibition increased expression of immune activation gene sets, including IFNγ signaling, and reduced immunosuppressive myeloid populations (86). This evidence concerns the gene AR and breast carcinoma.